-Approximately 40 million people in the U.S. suffer from migraine and there has been minimal improvement in standard of care acute treatment of migraine since the 1990s
-Rimegepant is an oral calcitonin gene-related peptide (CGRP) antagonist being developed for the acute and preventive treatment of migraine
-Results published in the New England Journal of Medicine demonstrate that, compared to placebo, a single-dose oral rimegepant provides superior, rapid freedom from pain and associated symptoms of migraine within two hours
PR Newswire
NEW HAVEN, Conn., July 10, 2019